loading
Schlusskurs vom Vortag:
$30.13
Offen:
$29.89
24-Stunden-Volumen:
386.40K
Relative Volume:
0.54
Marktkapitalisierung:
$1.96B
Einnahmen:
$87.56M
Nettoeinkommen (Verlust:
$-167.47M
KGV:
-12.89
EPS:
-2.34
Netto-Cashflow:
$-148.20M
1W Leistung:
+0.50%
1M Leistung:
+4.76%
6M Leistung:
-32.93%
1J Leistung:
-15.49%
1-Tages-Spanne:
Value
$29.84
$30.78
1-Wochen-Bereich:
Value
$29.15
$31.47
52-Wochen-Spanne:
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
Firmenname
Kymera Therapeutics Inc
Name
Telefon
857-285-5314
Name
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
Mitarbeiter
208
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-21
Name
Neueste SEC-Einreichungen
Name
KYMR's Discussions on Twitter

Vergleichen Sie KYMR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KYMR
Kymera Therapeutics Inc
30.17 1.95B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Eingeleitet Citigroup Buy
2024-12-10 Eingeleitet BTIG Research Buy
2024-12-06 Eingeleitet BMO Capital Markets Market Perform
2024-12-02 Hochstufung Wells Fargo Equal Weight → Overweight
2024-11-18 Eingeleitet Stephens Overweight
2024-09-09 Fortgesetzt Leerink Partners Outperform
2024-08-26 Hochstufung Wolfe Research Peer Perform → Outperform
2024-04-22 Eingeleitet Oppenheimer Outperform
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2024-01-04 Hochstufung JP Morgan Neutral → Overweight
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-12-19 Herabstufung Wells Fargo Overweight → Equal Weight
2023-06-30 Eingeleitet Truist Buy
2023-05-05 Hochstufung Raymond James Mkt Perform → Outperform
2022-12-06 Herabstufung Credit Suisse Outperform → Neutral
2022-11-08 Eingeleitet Raymond James Mkt Perform
2022-08-15 Eingeleitet Jefferies Buy
2022-08-03 Eingeleitet Goldman Buy
2022-07-20 Eingeleitet SVB Leerink Mkt Perform
2022-04-28 Eingeleitet Credit Suisse Outperform
2022-03-10 Eingeleitet JP Morgan Neutral
2022-02-10 Eingeleitet Wells Fargo Overweight
2021-09-30 Eingeleitet B. Riley Securities Neutral
2021-09-30 Eingeleitet Stifel Buy
2021-09-10 Herabstufung BofA Securities Buy → Neutral
2021-05-21 Eingeleitet UBS Buy
2021-04-14 Eingeleitet Berenberg Buy
2020-12-04 Eingeleitet H.C. Wainwright Buy
2020-09-15 Eingeleitet BofA Securities Neutral
2020-09-15 Eingeleitet Cowen Outperform
2020-09-15 Eingeleitet Guggenheim Buy
2020-09-15 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten

pulisher
May 20, 2025

Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data for Asthma Treatment | KYMR Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com

May 19, 2025
pulisher
May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics presents preclinical data for KT-621 - TipRanks

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference | KYMR Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan

May 19, 2025
pulisher
May 14, 2025

Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com

May 14, 2025
pulisher
May 14, 2025

Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha

May 14, 2025
pulisher
May 13, 2025

Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus

May 13, 2025
pulisher
May 13, 2025

UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st

May 13, 2025
pulisher
May 13, 2025

When the Price of (KYMR) Talks, People Listen - news.stocktradersdaily.com

May 13, 2025
pulisher
May 12, 2025

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK

May 12, 2025
pulisher
May 12, 2025

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech

May 12, 2025
pulisher
May 12, 2025

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks

May 12, 2025
pulisher
May 10, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases - Investing.com

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World

May 10, 2025
pulisher
May 10, 2025

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India

May 10, 2025
pulisher
May 10, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com

May 10, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Future Developments | KYMR Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa

May 09, 2025
pulisher
May 09, 2025

Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 09, 2025
pulisher
May 09, 2025

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research

May 09, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus

May 09, 2025

Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):